Neurocrine Biosciences
Develops and commercializes neuroscience and rare-disease medicines led by INGREZZA.
$154.94
After-hours close+0.88 (+0.57%)
At close$154.06(−1.19%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions 124.37%Insiders 1.12%
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 100.55M · Float 100.38M · 99.8% free float
Institutions13F, as of Jun 30, 2026
791 holders · 125.05M shares · 150 new positions · 462 increased · 226 reduced · 75 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 13.71M | 13.64% | +326.0K | Aug 7, 2026 |
| JPMorgan Chase & Co | 6.40M | 6.36% | +956.6K | Aug 12, 2026 |
| Dodge & Cox | 5.58M | 5.55% | +123.7K | Aug 13, 2026 |
| Vanguard Portfolio Management LLC | 4.97M | 4.95% | +247.7K | Aug 13, 2026 |
| Vanguard Capital Management LLC | 4.55M | 4.52% | +33.4K | Aug 13, 2026 |
| State Street Corp | 4.39M | 4.36% | +31.1K | Aug 7, 2026 |
| AQR Capital Management LLC | 3.82M | 3.80% | −1.12M | Aug 14, 2026 |
| Renaissance Technologies LLC | 2.34M | 2.32% | −83.0K | Aug 13, 2026 |
Beneficial owners13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 12.10% | 12.05M | 13G | Apr 28, 2025 ↗ |
| Dodge & Cox | 5.60% | 5.53M | 13G | May 14, 2025 ↗ |
| Vanguard Capital Management | 5.23% | 5.26M | 13G | Apr 30, 2026 ↗ |
| JPMorgan Chase & Co. | 5.20% | 5.20M | 13G | Jan 21, 2026 ↗ |
| State Street Corporation | 5.10% | 5.15M | Oct 17, 2024 ↗ |
InsidersForm 4
| Insider | Role | Shares | % outstanding | Filed |
|---|---|---|---|---|
| Kevin Charles Gorman | director | 511.3K | 0.51% | May 21, 2026 |
| Kyle Gano | director, officer: Chief Executive Officer | 145.0K | 0.14% | Feb 17, 2026 |
| Gary A. Lyons | director | 122.1K | 0.12% | May 21, 2026 |
| Darin Lippoldt | officer: Chief Legal Officer | 54.7K | 0.05% | Jul 13, 2026 |
| Eric Benevich | officer: Chief Commercial Officer | 54.6K | 0.05% | Feb 17, 2026 |
| William H. Rastetter | director | 43.7K | 0.04% | May 21, 2026 |
| Matt Abernethy | officer: Chief Financial Officer | 42.8K | 0.04% | Mar 5, 2026 |
| Richard F. Pops | director | 37.8K | 0.04% | May 21, 2026 |
| Julie Cooke | officer: Chief Human Resources Officer | 22.4K | 0.02% | Jun 4, 2026 |
| Jude Onyia | officer: Chief Scientific Officer | 21.0K | 0.02% | Aug 5, 2026 |
3 ten-percent owners hold 8.85M shares by Form 4, outside the officers-and-directors figure above · 18 people have not refiled in the last 18 months (1.19M shares), so they are not in the figure above
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Jul 28, 2026 | Leslie V. Norwalkdirector | Sale | 1,250 | $182.01 | 1,588 |
| Jul 9, 2026 | Darin Lippoldtofficer: Chief Legal Officer | Sale | 10,000 | $179.60 | 54,729 |
| Jul 10, 2026 | Ingrid Delaetofficer: Chief Regulatory Officer | Sale | 4,367 | $181.02 | 16,225 |
| Jul 9, 2026 | Ingrid Delaetofficer: Chief Regulatory Officer | Sale | 8,433 | $178.72 | 16,225 |
| Jul 7, 2026 | Ingrid Delaetofficer: Chief Regulatory Officer | Sale | 3,401 | $178.57 | 16,225 |
| Jul 8, 2026 | Ingrid Delaetofficer: Chief Regulatory Officer | Sale | 2,737 | $178.54 | 16,225 |
| Jun 29, 2026 | Darin Lippoldtofficer: Chief Legal Officer | Sale · 2 lots | 9,800 | $170.16 | 54,729 |
| Jun 26, 2026 | Darin Lippoldtofficer: Chief Legal Officer | Sale | 200 | $169.57 | 54,729 |
| Jun 5, 2026 | Stephen A. Sherwindirector | Sale · 5 lots | 25,000 | $165.32 | 15,860 |
| Jun 4, 2026 | Leslie V. Norwalkdirector | Sale | 1,250 | $168.06 | 2,838 |
CongressHouse and Senate disclosures
Not reported.